Stenzinger, Albrecht

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,683

Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors

Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 859

Accurate and efficient detection of gene fusions from RNA sequencing data

Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research

Cancer Genomics and DiagnosticsGenomics and Phylogenetic Studies

Cited by 526

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., et al. (2021) · Cancer Discovery

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 290

Homologous Recombination Deficiency: Concepts, Definitions, and Assays

Stewart, M. D., Merino Vega, D., Arend, R. C., Baden, J. F., Barbash, O., Beaubier, N., Collins, G., French, T., Ghahramani, N., Hinson, P., et al. (2022) · The Oncologist

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 240

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 203

Morphological and molecular breast cancer profiling through explainable machine learning

Binder, A., Bockmayr, M., Hägele, M., Wienert, S., Heim, D., Hellweg, K., Ishii, M., Stenzinger, A., Hocke, A., Denkert, C., et al. (2021) · Nature Machine Intelligence

AI in cancer detectionRadiomics and Machine Learning in Medical Imaging

Cited by 156

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E-mutated multiple myeloma

Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 48

Structure and content of the EU-IVDR: Current status and implications for pathology

Kahles, A., Goldschmid, H., Volckmar, A.-L., Ploeger, C., Kazdal, D., Penzel, R., Budczies, J., Kempny, G., Kazmierczak, M., Flechtenmacher, C., et al. (2023) · Die Pathologie

Healthcare RegulationClinical Laboratory Practices and Quality Control

Cited by 27

Laboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks

Vogeser, M., Brüggemann, M., Lennerz, J., Stenzinger, A., & Gassner, U. M. (2021) · Clinical Chemistry

Healthcare RegulationClinical Laboratory Practices and Quality Control

Cited by 22

Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia

Dieterle, M. P., Husari, A., Prozmann, S. N., Wiethoff, H., Stenzinger, A., Röhrich, M., Pfeiffer, U., Kießling, W. R., Engel, H., Sourij, H., et al. (2023) · Biomedicines

Pancreatic function and diabetesNeuroendocrine Tumor Research Advances

Cited by 19

An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS)

Dieterle, M. P., Husari, A., Prozmann, S. N., Wiethoff, H., Stenzinger, A., Röhrich, M., Pfeiffer, U., Kießling, W. R., Engel, H., Sourij, H., et al. (2023) · Biomedicines

Neuroendocrine Tumor Research AdvancesPancreatic function and diabetes

Cited by 5